MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Mereo BioPharma Group plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.30−0.00 (-0.30%)
Close on Oct 19, 2026
- Market cap
- $242.76M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
7.1%
57M of 798M shares
Institutional holders
61
15 new, 17 sold out
Net institutional buying
-19M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 74,500,000 | 9.40% | 13G (passive) | Jan 2, 2026 |
| Ari Zweiman | 65,083,815 | 8.18% | 13G (passive) | Dec 29, 2025 |
| Michael P. Rubin | 54,521,000 | 6.90% | 13G (passive) | Jun 4, 2025 |
| Bank Of America Corp /De/ | 40,976,460 | 5.10% | 13G (passive) | Mar 31, 2026 |
| James N. Topper | 40,349,315 | 5.10% | 13G (passive) | Apr 1, 2025 |
| David Rosen | 108,486,735 | – | 13D (active) amendment | Jun 17, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MREO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 15,307,347 | 1.92% | $4.86M | – | 0.04% |
| 683 Capital Management, LLC | 11,777,856 | 1.48% | $3.74M | −222,144 | 0.18% |
| Bank Of America Corp /De/ | 8,195,281 | 1.03% | $2.60M | −6 | 0.00% |
| Defilade Capital Management, L.P. | 7,558,756 | 0.95% | $2.40M | – | 0.32% |
| Newtyn Management, LLC | 3,000,000 | 0.38% | $953.10K | −4,079,056 | 0.12% |
| Tejara Capital Ltd | 2,037,520 | 0.26% | $647.32K | – | 0.27% |
| UBS Group AG | 1,447,627 | 0.18% | $460.35K | −42,501 | 0.00% |
| Two Sigma Investments, LP | 1,319,241 | 0.17% | $419.12K | +1,131,402 | 0.00% |
| EcoR1 Capital, LLC | 1,000,000 | 0.13% | $317.70K | −12,368,855 | 0.02% |
| Jane Street Group, LLC | 774,944 | 0.10% | $246.20K | +634,971 | 0.00% |
| Ishara Investments LP | 768,750 | 0.10% | $244.23K | New | 0.18% |
| Wealthspire Advisors, LLC | 765,000 | 0.10% | $243.04K | −31,036 | 0.00% |
| Citadel Advisors LLC | 444,158 | 0.06% | $141.11K | New | 0.00% |
| Rangeley Capital, LLC | 329,200 | 0.04% | $104.59K | – | 0.10% |
| Susquehanna International Group, Llp | 213,270 | 0.03% | $67.76K | +17,350 | 0.00% |
| Marshall Wace, Llp | 179,884 | 0.02% | $57.56K | −507,103 | 0.00% |
| XTX Topco Ltd | 174,481 | 0.02% | $55.43K | +90,012 | 0.00% |
| Group One Trading, L.P. | 167,515 | 0.02% | $53.22K | −168,312 | 0.00% |
| State Street Corp | 134,772 | 0.02% | $42.82K | +1,393 | 0.00% |
| Nomura Holdings Inc | 104,361 | 0.01% | $33.16K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 61 | 57M | 7.1% | 15 / 13 | 12 / 17 | 4M | 22M |
| Q1 2026 | 63 | 75M | 9.4% | 15 / 15 | 16 / 22 | 34M | 20M |
| Q4 2025 | 70 | 62M | 7.8% | 22 / 15 | 20 / 35 | 30M | 68M |
| Q3 2025 | 84 | 100M | 12.6% | 14 / 23 | 23 / 16 | 16M | 14M |
| Q2 2025 | 86 | 99M | 12.4% | 12 / 31 | 19 / 16 | 8M | 20M |
| Q1 2025 | 90 | 111M | 13.9% | 13 / 27 | 21 / 14 | 16M | 20M |
| Q4 2024 | 91 | 115M | 14.4% | 21 / 19 | 27 / 7 | 15M | 5M |
| Q3 2024 | 77 | 106M | 13.2% | 11 / 20 | 22 / 12 | 12M | 7M |
| Q2 2024 | 79 | 101M | 12.6% | 15 / 20 | 27 / 15 | 28M | 14M |
| Q1 2024 | 80 | 87M | 10.9% | 28 / 24 | 12 / 11 | 24M | 15M |
| Q4 2023 | 64 | 79M | 9.8% | 17 / 19 | 13 / 9 | 12M | 4M |
| Q3 2023 | 56 | 71M | 8.8% | 10 / 13 | 15 / 6 | 15M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MREO | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 134,772 | 0.02% | $42.82K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 92,534 | 0.01% | $31.83K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 14,500 | 0.00% | $4.61K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Denise Scots-Knight | Chief Executive Officer, Director | 808,921 | 0.10% | Feb 2, 2026 |
| Alexandra Hughes-Wilson | See Remarks | 134,483 | 0.02% | Feb 2, 2026 |
| Charles Sermon | General Counsel | 219,061 | 0.03% | Feb 2, 2026 |
| John A. Lewicki | Chief Scientific Officer | 92,826 | 0.01% | Feb 2, 2026 |
| Christine Ann Fox | Chief Financial Officer | 89,285 | 0.01% | Feb 2, 2026 |
| Pierre Jacquet | Director | – | – | Feb 27, 2026 |
| Anders Ekblom | Director | 37,940 | 0.00% | Feb 27, 2026 |
| Jeremy Bender | Director | 12,550 | 0.00% | Feb 27, 2026 |
| Daniel Shames | Director | – | – | Feb 27, 2026 |
| Deepika Pakianathan | Director | 1,825 | 0.00% | Feb 27, 2026 |
| Michael S. Wyzga | Director | 25,050 | 0.00% | Feb 27, 2026 |
| Annalisa Jenkins | Director | – | – | Feb 27, 2026 |
| Marc J. Yoskowitz | Director | – | – | Feb 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John A. Lewicki Chief Scientific Officer | Sep 13, 2024 | Sale | −10,937 | $4.22 | $46.15K | 78,630 |
| Christine Ann Fox Chief Financial Officer | Sep 13, 2024 | Sale | −19,158 | $4.22 | $80.85K | 89,285 |
| Charles Sermon General Counsel | Sep 13, 2024 | Sale | −20,946 | $4.22 | $88.39K | 219,061 |
| Alexandra Hughes-Wilson See Remarks | Sep 13, 2024 | Sale | −16,304 | $4.22 | $68.80K | 134,483 |
| Alexandra Hughes-Wilson See Remarks | Sep 13, 2024 | Sale | −84,008 | $4.22 | $354.51K | 50,475 |
| Denise Scots-Knight Chief Executive Officer, Director | Sep 13, 2024 | Sale | −60,046 | $4.22 | $253.39K | 808,921 |
| John A. Lewicki Chief Scientific Officer | Sep 12, 2024 | Sale | −5,212 | $4.47 | $23.30K | 89,567 |
| Christine Ann Fox Chief Financial Officer | Sep 12, 2024 | Sale | −9,128 | $4.47 | $40.80K | 108,443 |
| Charles Sermon General Counsel | Sep 12, 2024 | Sale | −9,980 | $4.47 | $44.61K | 240,007 |
| Alexandra Hughes-Wilson See Remarks | Sep 12, 2024 | Sale | −7,769 | $4.47 | $34.73K | 190,816 |
| Alexandra Hughes-Wilson See Remarks | Sep 12, 2024 | Sale | −40,029 | $4.47 | $178.93K | 150,787 |
| Denise Scots-Knight Chief Executive Officer, Director | Sep 12, 2024 | Sale | −28,611 | $4.47 | $127.89K | 868,967 |
| Christine Ann Fox Chief Financial Officer | Sep 11, 2024 | Option exercise | +60,000 | – | – | 117,571 |
| Denise Scots-Knight Chief Executive Officer, Director | Sep 11, 2024 | Option exercise | +188,060 | – | – | 897,578 |
| John A. Lewicki Chief Scientific Officer | Sep 11, 2024 | Option exercise | +46,000 | – | – | 94,779 |
| Alexandra Hughes-Wilson See Remarks | Sep 11, 2024 | Option exercise | +75,000 | $1.01 | $75.75K | 242,881 |
| Alexandra Hughes-Wilson See Remarks | Sep 11, 2024 | Option exercise | +40,000 | – | – | 74,548 |
| Alexandra Hughes-Wilson See Remarks | Sep 11, 2024 | Option exercise | +93,333 | $1.40 | $130.67K | 167,881 |
| Charles Sermon General Counsel | Sep 11, 2024 | Option exercise | +65,600 | – | – | 249,987 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +1,825 | $3.00 | $5.48K | 1,825 |
| Deepika Pakianathan Director | Aug 22, 2024 | Sale | −105,244 | $4.43 | $466.23K | 0 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +6,492 | $1.84 | $11.95K | 8,317 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +38,953 | $1.31 | $51.03K | 59,688 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +12,418 | $2.72 | $33.78K | 20,735 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +2,071 | $3.87 | $8.01K | 105,244 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +43,485 | $0.94 | $40.88K | 103,173 |
| Denise Scots-Knight Chief Executive Officer, Director | Jun 26, 2024 | Sale | −92,273 | $3.39 | $312.81K | 709,518 |
| Charles Sermon General Counsel | Jun 26, 2024 | Sale | −32,187 | $3.39 | $109.11K | 184,387 |
| Christine Ann Fox Chief Financial Officer | Jun 26, 2024 | Sale | −29,439 | $3.39 | $99.80K | 57,571 |
| John A. Lewicki Chief Scientific Officer | Jun 26, 2024 | Sale | −16,808 | $3.39 | $56.98K | 48,779 |
| Alexandra Hughes-Wilson See Remarks | Jun 26, 2024 | Sale | −22,968 | $3.39 | $77.86K | 34,548 |
| Denise Scots-Knight Chief Executive Officer, Director | Jun 25, 2024 | Sale | −40,712 | $3.69 | $150.23K | 801,791 |
| Charles Sermon General Counsel | Jun 25, 2024 | Sale | −14,202 | $3.69 | $52.41K | 216,574 |
| Christine Ann Fox Chief Financial Officer | Jun 25, 2024 | Sale | −12,990 | $3.69 | $47.93K | 87,010 |
| John A. Lewicki Chief Scientific Officer | Jun 25, 2024 | Sale | −7,416 | $3.69 | $27.37K | 65,587 |
| Alexandra Hughes-Wilson See Remarks | Jun 25, 2024 | Sale | −10,134 | $3.69 | $37.39K | 57,516 |
| Charles Sermon General Counsel | Jun 21, 2024 | Option exercise | +98,400 | – | – | 230,776 |
| Alexandra Hughes-Wilson See Remarks | Jun 21, 2024 | Option exercise | +60,000 | – | – | 67,650 |
| Denise Scots-Knight Chief Executive Officer, Director | Jun 21, 2024 | Option exercise | +282,090 | – | – | 842,503 |
| John A. Lewicki Chief Scientific Officer | Jun 21, 2024 | Option exercise | +69,000 | – | – | 73,003 |
| Christine Ann Fox Chief Financial Officer | Jun 21, 2024 | Option exercise | +90,000 | – | – | 100,000 |
| Jeremy Bender Director | Jun 17, 2024 | Award | +12,550 | $3.99 | $50.07K | 12,550 |
| Michael S. Wyzga Director | Jun 17, 2024 | Award | +25,050 | $3.99 | $99.95K | 25,050 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Sale | −50,082 | $2.94 | $147.24K | 32,568 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Option exercise | +75,000 | $1.01 | $75.75K | 82,650 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Tax withholding | −42,983 | $1.40 | $60.18K | 7,650 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Sale | −50,350 | $2.99 | $150.55K | 58,633 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Option exercise | +93,333 | $1.40 | $130.67K | 100,983 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Tax withholding | −24,918 | $1.01 | $25.17K | 7,650 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John A. Lewicki Officer | Sep 12, 2024 | 16,149 | $75.25K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Denise Scots-Knight Officer, Director | Sep 12, 2024 | 88,657 | $413.14K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Charles Sermon Officer | Sep 12, 2024 | 30,926 | $144.12K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Christine Ann Fox Officer | Sep 12, 2024 | 28,286 | $131.81K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Hughes-Wilson Alexandra Officer | Sep 12, 2024 | 148,110 | $690.19K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Pakianathan Deepika Director | Aug 22, 2024 | 105,244 | $466.21K | Aug 22, 2024 | Exercise of option under a registered plan |
| Hughes-Wilson Alexandra Officer | Jun 24, 2024 | 33,102 | $131.75K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| Denise Scots-Knight Officer, Director | Jun 24, 2024 | 146,284 | $582.21K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| Charles Sermon Officer | Jun 24, 2024 | 51,028 | $203.09K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| Christine Ann Fox Officer | Jun 24, 2024 | 46,672 | $185.75K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| John A. Lewicki Officer | Jun 24, 2024 | 26,647 | $106.06K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| Christine Ann Fox Officer | Jun 20, 2024 | 46,672 | $185.75K | Jun 21, 2024 | Same Day Cashless Exercise and Sale |
| Hughes-Wilson Alexandra Officer | Jun 20, 2024 | 33,102 | $131.75K | Jun 21, 2024 | Same Day Cashless Exercise and Sale |
| John A. Lewicki Officer | Jun 20, 2024 | 26,647 | $106.06K | Jun 21, 2024 | Same Day Cashless Exercise and Sale |
| Denise Scots-Knight Officer, Director | Jun 20, 2024 | 146,284 | $582.21K | Jun 21, 2024 | Same Day Cashless Exercise and Sale |